

## Pharmacy & Therapeutics Committee Meeting

### Notice of Public Meeting

State of Alaska

Department of Health & Social Services

Division of Health Care Services

The Division will be sponsoring the following meeting to address the Preferred Drug List.

Please note, as a result of COVID-19 this meeting will be available via webinar only.

**Please register for the meeting by using the link below:**

**[https://magellanhealth.zoom.us/webinar/register/WN\\_vzWnFCUQSHWdCWPMobfzGg](https://magellanhealth.zoom.us/webinar/register/WN_vzWnFCUQSHWdCWPMobfzGg)**

**If you are calling in only through the webinar:**

**\*6 to Toggle mute/unmute and \*9 to Raise Hand**

**After registering, you will receive a confirmation email containing information about joining the webinar.**

The Pharmacy and Therapeutics Committee will meet Friday, September 17, 2021 at 8:00 a.m. Agendas are posted on the Health Care Services Preferred Drug List Program Overview website

<https://manuals.medicaidalaska.com/docs/pharmacy.htm>.

Any pharmaceutical manufacturer may submit unsolicited material related to the agenda items by utilizing the Clinical Submission form. Clinical Submissions will be accepted until September 3, 2021 at 4:00pm AK local time. Forms may be found at: <https://manuals.medicaidalaska.com/docs/pharmacy.htm>

Any member of the public, including health care professionals, may submit unsolicited material related to the agenda items, by utilizing the Clinical Submission form found at:

<https://manuals.medicaidalaska.com/docs/pharmacy.htm>. A conflict of interest form must accompany any submission and can be found at: <http://dhss.alaska.gov/dhcs/Documents/pharmacy/forms/Alaska-Medicaid-Clinical-Coverage-Review-Request-Disclosure-Form.pdf>. Submissions should be received no later than September 15, 2021 to allow inclusion in the meeting. If you can not join the webinar and would like to join via teleconference, please dial 1.800.315.6338, use access code 24251#.

Individuals with disabilities who need special accommodations in order to participate should contact Charles Semling at 907.334.2458 no later than 2:00 p.m., Wednesday, September 15, 2021.

**Alaska Medicaid Pharmacy and Therapeutics Committee  
Meeting September 17, 2021**

Please note, as a result of COVID-19 this meeting will be available via webinar.

**Please register for the meeting by using the link below:**

[https://magellanhealth.zoom.us/webinar/register/WN\\_vzWnFCUQSHWdCWPMobfzGg](https://magellanhealth.zoom.us/webinar/register/WN_vzWnFCUQSHWdCWPMobfzGg)

If you are calling in only through the webinar:

\*6 to Toggle mute/unmute and \*9 to Raise Hand

After registering, you will receive a confirmation email containing information about joining the webinar.

**Agenda**

For anyone unable to access the webinar:

1.800.315.6338. Access code **24251#**

- |           |                              |                |
|-----------|------------------------------|----------------|
| <b>1.</b> | <b>Call to Order – Chair</b> | <b>8:00 am</b> |
| <b>2.</b> | <b>Roll Call</b>             | <b>8:05 am</b> |
| <b>3.</b> | <b>Public Comment</b>        |                |

The Department’s methods for class review are to better utilize the time of the P&T Committee. Classes shown in **Red** are *new classes/new drugs* and **Blue** are classes where *\*\*new information exists and industry testimony will be taken*. Classes shown in **Green** are classes with no significant changes have been noted and no industry testimony will be taken.

\*\*New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.

**4. Class review, discussion & vote.**

AK Treatment Class	Drug Class	Status
<b>Gastrointestinal</b>	Antiemetic-Antivertigo Agents	<b>GREEN</b>
	GI Motility & Irritable Bowel Syndrome, Chronic	<b>GREEN</b>
	Ulcerative Colitis	<b>GREEN</b>
	Cytokine & Cell-Adhesion Molecules (CAM) Antagonist – <i>GI indicated</i>	<b>BLUE</b>
<b>Endocrine/ Metabolic</b>	Antihyperuricemics	<b>GREEN</b>
	Progestins for Cachexia	<b>GREEN</b>
	Growth Hormone	<b>RED</b>
	Androgenic Agents, Topical	<b>GREEN</b>
	Bone Resorption Inhibitors	<b>GREEN</b>
	Hypoglycemics, Metformin	<b>BLUE</b>
	Hypoglycemics, Alpha-Glucosidase Inhibitors	<b>GREEN</b>
	Hypoglycemics, SGLT2 Inhibitors	<b>BLUE</b>
	Hypoglycemics, Meglitinides	<b>GREEN</b>
	Hypoglycemics, Thiazolidinedione (TZD) and Combinations	<b>GREEN</b>
	Hypoglycemics, Dipeptidyl Peptidase-4 Inhib. (DPP-4) and Combinations	<b>BLUE</b>
	Hypoglycemics, Glucagon-like Peptide-1 (GLP-1) and Combinations	<b>BLUE</b>
	Rapid-Acting Insulins	<b>GREEN</b>
	Regular Insulins	<b>GREEN</b>
Intermediate Insulins	<b>GREEN</b>	
Rapid/Intermediate-Acting Combination Insulins	<b>GREEN</b>	

	Regular/Intermediate-Acting Combination Insulins	<b>GREEN</b>
	Long-Acting Insulins	<b>BLUE</b>
	Phosphate Binders	<b>GREEN</b>
<b>Antiretrovirals</b>	HIV/AIDs	<b>RED</b>
<b>Single Class Review</b>	Movement Disorders	<b>RED</b>
	Continuous Glucose Monitors	<b>RED</b>

**Break as needed – 15 minutes**

- 7. Review minutes from April 2021 meeting**
- 8. Comments from Committee Members or Chair**
- 9. Adjourn**

*Next Meeting Date: November 19, 2021*

## NOTICE OF PUBLIC MEETING

State of Alaska  
Department of Health & Social Services  
Division of Health Care Services

The Division will be sponsoring the following meeting to address the Drug Utilization Review.

**Please note, as a result of COVID-19 this meeting will be available via teleconference only.**

The Drug Utilization Review Committee will meet Friday, September 17, 2021 at 1:00 p.m. Agendas are posted on the Health Care Services Drug Utilization website <https://manuals.medicaidalaska.com/docs/pharmacy.htm>. If you would like to join via teleconference, please dial 1.800.315.6338, use access code 24251#.

Any pharmaceutical manufacturer may submit unsolicited material related to the agenda items by utilizing the Clinical Submission form. Clinical Submissions will be accepted until September 3, 2021 at 4:00pm AK local time. Forms may be found at: <https://manuals.medicaidalaska.com/docs/pharmacy.htm>

Any member of the public, including health care professionals, may submit unsolicited material related to the agenda items by sending an email to [charles.semaling@alaska.gov](mailto:charles.semaling@alaska.gov) or via mail to 4601 Business Park Blvd, Bldg K, Anchorage, AK 99503. A conflict of interest form must accompany any submission and can be found at: <http://dhss.alaska.gov/dhcs/Documents/pharmacy/forms/Alaska-Medicaid-Clinical-Coverage-Review-Request-Disclosure-Form.pdf>. Submissions should be received no later than September 15, 2021 to allow inclusion in the meeting.

Individuals with disabilities who need special accommodations in order to participate should contact Charles Semling at 907.334.2458 no later than 2:00 p.m., Wednesday, September 15, 2021.



Alaska Medical Assistance DUR Committee Meeting  
Friday September 17, 2021  
Frontier Building, 3601 C Street; Room 896  
1:00pm  
1.800.315.6338, access code 24251#

**Please note, as a result of COVID-19 this meeting will be available via teleconference only.**

## Agenda

- (1) Review of minutes from April
- (2) Review of Agenda
- (3) Comments/Suggestions from Committee members
- (4) Overview of Medicaid Prescription and Cost Trends
- (5) Prospective Drug Utilization Review / Clinical Topic Areas:
  - a. New Prescription Medications (Interim PA List – 6 month review)
    - i. Review of new medications to market since the April meeting
    - ii. Review of Quantity limit list
  - b. New Prior Authorizations, Quantity Limits, Edits
    - i. Lupkynis
    - ii. Isturisa
    - iii. Aduhelm
  - c. Review of existing Prior Authorizations, Quantity Limits, Edits
    - i. Myfembree
    - ii. Vancocin
- (6) Opioid Use Trends and ICD-10 Report
- (7) Opioid/ Sedative Edit
- (8) FDA/DEA Updates
  - a. FDA Drug Safety Communications
- (9) FAERS Reports
- (10) Misc. DUR items
- (11) End of Public Meeting
- (12) Profile Review

*Pharmaceutical Manufacturers wishing to submit unsolicited clinical information may do so via the form found at the link below:*

<https://manuals.medicaidalaska.com/docs/pharmacy.htm>

*Submissions for the September meeting must be received no later than 4pm Alaska local time on September 3, 2021.*